Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination.

Literature DB >> 24993880

Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination.

Wendy T Parker¹, Stuart R Phillis², David T O Yeung³, Timothy P Hughes⁴, Hamish S Scott⁵, Susan Branford⁵.

Abstract

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 24993880 DOI： 10.1182/blood-2014-05-573485

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

× No keyword cloud information.

8 in total

1. Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN.

Authors: S Jeromin; A Kohlmann; M Meggendorfer; S Schindela; K Perglerová; N Nadarajah; W Kern; C Haferlach; T Haferlach; S Schnittger
Journal: Leukemia Date: 2015-07-29 Impact factor: 11.528

2. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.

Authors: Constance Baer; Wolfgang Kern; Sarah Koch; Niroshan Nadarajah; Sonja Schindela; Manja Meggendorfer; Claudia Haferlach; Torsten Haferlach
Journal: Haematologica Date: 2016-04-21 Impact factor: 9.941

Review 3. Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.

Authors: Christopher A Eide; Thomas O'Hare
Journal: Curr Hematol Malig Rep Date: 2015-06 Impact factor: 3.952

4. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Authors: Michael W Deininger; J Graeme Hodgson; Neil P Shah; Jorge E Cortes; Dong-Wook Kim; Franck E Nicolini; Moshe Talpaz; Michele Baccarani; Martin C Müller; Jin Li; Wendy T Parker; Stephanie Lustgarten; Tim Clackson; Frank G Haluska; Francois Guilhot; Hagop M Kantarjian; Simona Soverini; Andreas Hochhaus; Timothy P Hughes; Victor M Rivera; Susan Branford
Journal: Blood Date: 2015-11-24 Impact factor: 22.113

Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination.

1. Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN.

2. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.

Review 3. Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.

4. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Review 5. Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.

6. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.

Review 7. MinION: A Novel Tool for Predicting Drug Hypersensitivity?

Review 8. Methodologies for Transcript Profiling Using Long-Read Technologies.